Medical device companies have been under fire recently. Pricing pressures, a down economy, cash-strapped hospitals, and a competitive landscape have sent sales reeling at several major firms. Boston Scientific (NYSE: BSX ) has been hit especially hard, with its cardiac rhythm management (CRM) and interventional cardiology businesses seeing revenues fall across the board.
This company won't sit by as its outlook wanes, however. Boston's Watchman atrial fibrillation device has been turned down once by the Food and Drug Administration already, but promising new trial data has breathed life back into this new technology. With the atrial fibrillation industry on the rise, is this just what Boston needed to save its cardiovascular business' future? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss that and more below.
5 Best Recreation Stocks To Buy For 2015: OncoSec Medical Inc (ONCS)
OncoSec Medical Incorporated, incorporated on February 8, 2008, is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.
The Company�� acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.
Advisors' Opinion:- [By Bio-Wire]
Another company that has benefitted from Inovio�� newfound attention is OncoSec Medical (OTC: ONCS) ��a newer ��ffshoot�� company that uses a similar but distinctly different electroporation device known as the OncoSec Medical System (OMS) that is based on Inovio�� technology. The specific amplitude and frequency of the OMS electroporation is calibrated such that plasmid delivery into solid tumor masses is fully optimized, while CELLECTRA electroporation is less specialized and focus more on the vaccination of skin cells. The cross-license agreement made between Inovio and Oncosec also covers the two devices for their distinctly different applications.
- [By John Udovich]
Small cap biotech stocks AVEO Pharmaceuticals, Inc (NASDAQ: AVEO), OncoSec Medical Inc (OTCMKTS: ONCS) and MetaStat Inc (OTCBB: MTST) are focused on or are developing treatments or diagnostic technologies for metastatic cancers. In case you aren�� familiar with the term metastasis or metastatic, it�� the�spread of cancer from its primary site to other places in the body as cancer cells break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream and then grow in a new focus (metastasize) in normal tissues elsewhere in the body. In other words, it�� a dangerous form of cancer, but there are some small cap biotech stocks targeting it for diagnostics or treatment:
- [By James E. Brumley]
If you're looking for the next big biotech breakout stock, then OncoSec Medical Inc. (OTCMKTS:ONCS) deserves a place on your watchlist. This volatile cancer play has been down more than up 2011, but if you look closely at a long-term chart of ONCS, you may find it's already wiggled its way into a new uptrend. And, it may be only a matter of time before the bullish fireworks start to go off.
- [By James E. Brumley]
How does the old saying go? Beggars can't be choosers? Two weeks ago, yours truly penned some bullish comments regarding OncoSec Medical Inc. (OTCMKTS:ONCS). The long and short of it was, if ONCS could clear a technical ceiling around $0.36, then life would get much easier for the bulls.
Hot Medical Stocks To Buy Right Now: Euromedis Groupe SA (EMG)
Euromedis Groupe SA is a France-based company that specializes in the design, manufacture, distribution, rental and export of medical and surgical equipment and products, and services for medical home care for hospitals, clinics, retirement homes, physicians, pharmacies, and individuals. The Company's product portfolio include products, such as syringes and needles; surgical equipment, such as catheters, instrumentation and compresses; gloves; hygiene products, comprising disposable clothing, masks and paper towel products, and pharmaceutical equipment, offering cotton wool and thermometers. Euromedis Groupe SA exports its products to Europe and Africa. Advisors' Opinion:- [By Sofia Horta e Costa]
Commodity producers increased as base metals rallied, with BHP Billiton Ltd. (BHP), the largest mining company, climbing 3.7 percent. Man Group (EMG) Plc soared 13 percent on a plan to redeem debt. Royal Bank of Scotland Group Plc dropped by the most in two months after Britain�� biggest state-owned lender reported operating profit that fell short of analysts��estimates.
- [By Sofia Horta e Costa]
Man Group Plc (EMG) jumped 6.8 percent to 104.3 pence. The world�� largest publicly traded hedge-fund manager said it no longer needs to hold a $300 million capital buffer after it confirmed with the U.K.�� Financial Conduct Authority a change in the company�� regulatory status.
Hot Medical Stocks To Buy Right Now: ImmunoCellular Therapeutics Ltd (IMUC)
ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).
The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.
The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.
Advisors' Opinion:- [By Monica Gerson]
ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.
Posted-In: market losersNews Movers & Shakers Intraday Update Markets
- [By Smith On Stocks]
Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.
Hot Medical Stocks To Buy Right Now: Oramed Pharmaceuticals Inc (ORMP)
Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.
The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.
Advisors' Opinion:- [By Ben Levisohn]
Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.
BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.
- [By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 21.26% to $14.20. The volume of Oramed Pharmaceuticals shares traded was 621% higher than normal. Oramed shares have jumped 187.01% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.
- [By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.
Hot Medical Stocks To Buy Right Now: Prothena Corporation PLC (PRTA)
Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company�� work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company�� program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tumor cells.
The Company�� pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.
NEOD001 for Amyloidosis
NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).
PRX002 for Parkinson�� Disease
The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkinson�� disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.
PRX003 for Inflammatory Diseases and Cancers
The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company�� antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.
Advisors' Opinion:- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) shares surged 23.52% to touch a new 52-week high of $45.90 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.
- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) rose 24.40% to $46.23 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.
- [By Jake L'Ecuyer]
Equities Trading UP
Prothena Corporation plc (NASDAQ: PRTA) shares shot up 21.60 percent to $45.19 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00. - [By Lauren Pollock]
Roche Holding AG(ROG.VX) has entered a pact with Prothena Corp.(PRTA) PLC to develop and commercialize a treatment the clinical-stage biotechnology firm is developing for Parkinson’s disease. In after-hours trading, Prothena’s stock rose 8.6% to $29.75 premarket.
Hot Medical Stocks To Buy Right Now: Opt-Sciences Corp (OPST)
Opt-Sciences Corporation, incorporated on November 1956, conducts its business through its wholly owned subsidiary, O and S Research, Inc. The Company deposits anti-glare and/or transparent conductive optical coatings on glass used primarily to cover instrument panels in aircraft cockpits. It also provides full glass cutting, grinding and painting operations, which augment its optical coating capabilities. Its products are designed to enable pilots to read aircraft instruments in direct sunlight or at night or in covert situations using appropriate night vision filters or to protect the instruments from electromagnetic interference. The Company�� business is dependent on a robust commercial, business, and regional aircraft market and to a lesser degree the military aircraft market. It generally has a four to twelve week delivery cycle depending on product complexity, available plant capacity and required lead time for specialty raw materials, such as polarizers or filter glass.
The Company�� offers incorporate an optical coating of some type. Its primary coatings are for aircraft cockpit display applications and consist of its anti-reflection coating used for glare reduction and its transparent conductive coating used for electromagnetic interference shielding. In addition, it also offers a full range of other specialty instrument glass, including night vision filter glass, circular polarizers, touchpads, glass sandwiches for liquid crystal displays (LCDs) as well as other custom designed specialty glass components and assemblies. It uses its technology to apply a micro thin optical non-glare and/or conductive coating to the glass. Both processes utilize the deposit of a thin film of metal or metal oxide on the surface of the glass. The process takes place in a heated vacuum chamber. It heats the deposited material to over 1800 degrees Centigrade causing it to evaporate.
The Company competes with JDSU, Mod A Can, Dontech, Schott Glass and Hoya Optics
Advisors' Opinion:- [By Geoff Gannon] ng>Micropac
Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.
ADDvantage
ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.
By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.
That�� pretty typical in the world of net-nets.
Solitron
Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO ��we��e still talking about a company where one person has a lot of control. Solitron only has three directors. Saraf is the chairman, CEO, president, CFO and treasurer. Neither of the other two directors joined the board within the last 15 years. So, we aren�� talking about a lot of tumult at the top.
In fact, profitable net-nets seem to be especially common candidates for abandoning the responsibilities of a public company without actually getting taken private.
OPT-Sciences
This company is controlled by Arthu
Hot Medical Stocks To Buy Right Now: NanoViricides Inc (NNVC)
NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company�� drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patients; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide - I against HIV/AIDS; HerpeCide - I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc's Inno-Haven LLC acquired a light industrial building.
The Company's product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD��) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses - epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.
The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide against adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.
The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 nano-biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.
If you take a look at the chart for Nanoviricides, you'll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.
Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday's high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.
Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment